Diabetes

Glucagon-like peptide-1 receptor agonists have gone Hollywood.

Get the info you need on this new product, part of our drug news roundup for February.

U.S. study suggests that semaglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist, may be useful to reduce alcohol consumption and craving in alcohol use disorder.

InsuJet, the first needleless device for insulin delivery, is now available in Canada. Can you tell which statement about this device is false?

Case series describes the rare development of nonarteritic anterior ischemic optic neuropathy (NAION) in new users of semaglutide or tirzepatide.

Study suggests risk of death is increased nearly 200%; lower with other diabetes treatments.

Study examines the comparative cardiovascular efficacy and safety of sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients with type 2 diabetes.

Advise patients to use sugar substitutes in moderation, emphasizing that they are a tool to complement, not replace, a healthy diet.